New hope for Hard-to-Treat cancers? early trial launches
NCT ID NCT07159126
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tests a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is an early-stage trial, so it focuses on safety and dosing, not on curing the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital
RECRUITINGChūōku, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.